Clinical efficacy of porcine pulmonary surfactant combined with budesonide suspension intratracheal instillation in the treatment of neonatal meconium aspiration syndrome
TAN Xiu-Zhen1, WU Shi-Guang1, ZHANG Jian-Hua1, LI Xiao-Fen1, GAO Ping-Ming2, WANG Yu3
Department of Neonatology, The 6th People's Hospital of Foshan Nanhai District, Foshan, Guangdong 528248, China
Abstract Objective To study the clinical efficacy of porcine pulmonary surfactant (PS) combined with budesonide suspension intratracheal instillation in the treatment of neonatal meconium aspiration syndrome (MAS). Methods Seventy neonates with MAS were enrolled for a prospective study. The neonates were randomly assigned to PS alone treatment group and PS+budesonide treatment group (n=35 each). The PS alone treatment group was given PS (100 mg/kg) by intratracheal instillation. The treatment group was given budesonide suspension (0.25 mg/kg) combined with PS (100 mg/kg). Results The rate of repeated use of PS in the PS+ budesonide group was significantly lower than that in the PS alone group 12 hours after treatment (P < 0.05). The improvement of PaO2/FiO2, TcSaO2, PaO2, and PaCO2 in the PS+ budesonide group was significantly greater than that in the PS alone group 6, 12, and 24 hours after treatment (P < 0.05). The chest X-ray examination showed that the pulmonary inflammation absorption in the PS+ budesonide group was significantly better than that in the PS alone group 48 hours after treatment (P < 0.05). The incidence of complications in the PS+budesonide group was significantly lower than that in the PS alone group (P < 0.05), and the average hospitalization duration was significantly shorter than that in the PS alone group (P < 0.01). Conclusions PS combined with budesonide suspension intratracheal instillation for the treatment of neonatal MAS is effective and superior to PS alone treatment.
TAN Xiu-Zhen,WU Shi-Guang,ZHANG Jian-Hua et al. Clinical efficacy of porcine pulmonary surfactant combined with budesonide suspension intratracheal instillation in the treatment of neonatal meconium aspiration syndrome[J]. CJCP, 2016, 18(12): 1237-1241.
TAN Xiu-Zhen,WU Shi-Guang,ZHANG Jian-Hua et al. Clinical efficacy of porcine pulmonary surfactant combined with budesonide suspension intratracheal instillation in the treatment of neonatal meconium aspiration syndrome[J]. CJCP, 2016, 18(12): 1237-1241.
Mokra D, Drgova A, Kopincova J, et al. Anti-inflammatory treatment in dysfunction of pulmonary surfactant in meconium-induced acute lung injury[J]. Adv Exp Med Biol, 2013, 756:189-196.
Liu YJ, Soumelis V, Watanabe N, et al. TSLP:an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation[J]. Annu Rev Immunol, 2007, 25:193-219.
Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis:a randomised, double blind, placebo controlled study[J]. Gut, 2005, 54(7):960-965.
[19]
Driban JB, Barr AE, Amin M, et al. Joint inflammation and early degeneration induced by high-force reaching are attenuated by ibuprofen in an animal model of work-related musculoskeletal disorder[J]. J Biomed Biotechnol, 2011, 2011:691412.
